Genovis AB (publ.) (GENO) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.059x

Based on the latest financial reports, Genovis AB (publ.) (GENO) has a cash flow conversion efficiency ratio of 0.059x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr15.90 Million ≈ $1.71 Million USD) by net assets (Skr271.52 Million ≈ $29.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Genovis AB (publ.) fund operations to measure how many days the company can operate on defensive assets alone.

Genovis AB (publ.) - Cash Flow Conversion Efficiency Trend (2008–2025)

This chart illustrates how Genovis AB (publ.)'s cash flow conversion efficiency has evolved over time, based on yearly financial data.

Genovis AB (publ.) Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Genovis AB (publ.) ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
DAE HWA Pharmaceutical Co. Ltd KQ:067080	0.004x
VYTRUS BIOTECH EO -01 F:V5P	N/A
Dynacolor TWO:5489	0.040x
Konya Kagit Sanayi ve Ticaret AS IS:KONKA	-0.023x
Fate Therapeutics Inc NASDAQ:FATE	-0.104x
Pantech Group Holdings Bhd KLSE:5125	-0.006x
Melnick Even Desenvolvimento Imobiliário S.A SA:MELK3	-0.002x
Lara Exploration Ltd. V:LRA	-0.091x

Annual Cash Flow Conversion Efficiency for Genovis AB (publ.) (2008–2025)

The table below shows the annual cash flow conversion efficiency of Genovis AB (publ.) from 2008 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Genovis AB (publ.) worth.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr271.52 Million ≈ $29.22 Million	Skr32.02 Million ≈ $3.45 Million	0.118x	-27.56%
2024-12-31	Skr227.97 Million ≈ $24.53 Million	Skr37.12 Million ≈ $3.99 Million	0.163x	-54.15%
2023-12-31	Skr190.81 Million ≈ $20.53 Million	Skr67.75 Million ≈ $7.29 Million	0.355x	+4908.05%
2022-12-31	Skr125.65 Million ≈ $13.52 Million	Skr-927.95K ≈ $-99.86K	-0.007x	-101.83%
2021-12-31	Skr113.99 Million ≈ $12.27 Million	Skr45.92 Million ≈ $4.94 Million	0.403x	+835.02%
2020-12-31	Skr87.17 Million ≈ $9.38 Million	Skr3.76 Million ≈ $404.12K	0.043x	-88.31%
2019-12-31	Skr35.62 Million ≈ $3.83 Million	Skr13.13 Million ≈ $1.41 Million	0.368x	+868.80%
2018-12-31	Skr26.07 Million ≈ $2.81 Million	Skr-1.25 Million ≈ $-134.48K	-0.048x	+89.57%
2017-12-31	Skr18.19 Million ≈ $1.96 Million	Skr-8.36 Million ≈ $-899.14K	-0.459x	+55.57%
2016-12-31	Skr15.55 Million ≈ $1.67 Million	Skr-16.08 Million ≈ $-1.73 Million	-1.034x	+43.40%
2015-12-31	Skr8.82 Million ≈ $949.39K	Skr-16.12 Million ≈ $-1.73 Million	-1.827x	-20.06%
2014-12-31	Skr14.58 Million ≈ $1.57 Million	Skr-22.19 Million ≈ $-2.39 Million	-1.522x	-303.82%
2013-12-31	Skr33.09 Million ≈ $3.56 Million	Skr-12.47 Million ≈ $-1.34 Million	-0.377x	+65.40%
2012-12-31	Skr13.63 Million ≈ $1.47 Million	Skr-14.85 Million ≈ $-1.60 Million	-1.089x	-61.46%
2011-12-31	Skr18.01 Million ≈ $1.94 Million	Skr-12.15 Million ≈ $-1.31 Million	-0.675x	+2.00%
2010-12-31	Skr15.23 Million ≈ $1.64 Million	Skr-10.48 Million ≈ $-1.13 Million	-0.688x	+45.43%
2009-12-31	Skr10.86 Million ≈ $1.17 Million	Skr-13.70 Million ≈ $-1.47 Million	-1.261x	+49.75%
2008-12-31	Skr6.68 Million ≈ $718.56K	Skr-16.76 Million ≈ $-1.80 Million	-2.510x	--

About Genovis AB (publ.)

ST:GENO Sweden Biotechnology

Market Cap

$131.52 Million

Skr1.22 Billion SEK

Market Cap Rank

#18244 Global

#312 in Sweden

Share Price

Skr18.50

Change (1 day)

-2.63%

52-Week Range

Skr16.16 - Skr29.50

All Time High

Skr87.00